Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 12th Milan Breast Cancer Conference
The ATAC Trial: 10-year Analysis
Milan, Italy / June 16-18, 2010
Milan - Studies have now established the efficacy of adjuvant third-generation aromatase inhibition over the antiestrogen tamoxifen in reducing the risk of breast cancer recurrence among postmenopausal women with hormone receptor-positive...
PRIORITY PRESS - 15th Congress of the European Hematology Association
Novel Agents Significantly Improve Outcomes in Multiple Myeloma
Barcelona, Spain / June 10-13, 2010
Barcelona - Novel agents, including a proteasome inhibitor and two immunomodulatory drugs, are changing the therapeutic landscape for multiple myeloma. Unlike in the past, the goal of treatment today is to attain complete remission....
MEDI-NEWS - Based on: Mateos et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28(13):2259-66.
Emerging Standard for Previously Untreated Multiple Myeloma Patients
June 2010
The standard first-line regimen for symptomatic multiple myeloma patients ineligible for high-dose chemotherapy preserves its survival advantage over the previous standard even when patients are followed across subsequent rescue regimens,...
MEDICAL FRONTIERS - 46th Annual Meeting of the American Society of Clinical Oncology
Update on Optimal Long-term Control of GIST with Targeted Therapies
Chicago, Illinois / June 4-8, 2010
Chicago - The efficacy of imatinib, an oral small molecule inhibitor in the long-term control of metastatic or unresectable gastrointestinal stromal tumours (GIST), has provided an impressive demonstration of the potency of targeted...
PRIORITY PRESS - 46th Annual Meeting of the American Society of Clinical Oncology
Enhancing Quality of Life for Metastatic Breast Cancer Patients
Chicago, Illinois / June 4-8, 2010
Chicago - New phase III comparative data have provided evidence for a rational first-line selection of a single-agent cytotoxic drug in the treatment of HER2-negative metastatic breast cancer (MBC). In guidelines such as those issued by the...
PRIORITY PRESS - 105th Annual Meeting of the American Urological Association
GnRH Antagonists: Advances in Androgen Deprivation Therapy for Prostate Cancer
San Francisco, California / May 29-June 3, 2010
San Francisco - GnRH agonists effectively suppress testosterone in over 90% of patients with advanced prostate cancer but can require as much as 30 days to achieve full suppressive effects, during which time testosterone levels actually...
PRIORITY PRESS - 25th Congress of the European Association of Urology
Androgen Deprivation Therapy in Prostate Cancer
Barcelona, Spain / April 16-20, 2010
Barcelona - New data have reinforced the utility of a gonadotropin-releasing hormone (GnRH) receptor blocker for slowing progression of advanced prostate cancer. Following a previous phase III study in which this agent compared favourably...
PRIORITY PRESS - 36th Annual Meeting of the European Group for Blood and Bone Marrow Transplantation (EBMT)
New Antifungal Strategies in High-risk Stem Cell Transplant Recipients
Vienna, Austria / March 21-24, 2010
Vienna - Although Candida infection is still probably the most widespread fungal infection in a surgical setting, Aspergillus and other mold pathogens are a substantial cause of morbidity and mortality in immunosuppressed patients. In...
PRIORITY PRESS - 36th Annual Meeting of the European Group for Blood and Bone Marrow Transplantation (EBMT)
Progress in Infection Management of Allogeneic Stem Cell Recipients
Vienna, Austria / March 21-24, 2010
Vienna - In the last 10 years, widespread use of allogeneic hematopoietic stem cell transplantation has decreased the risk of recurrence in patients with aggressive hematological malignancies. However, the associated conditioning and...